Table 8 |
||||
|
PROGRESS DrotAA mortality and clinical outcomes |
||||
|
Variable |
DrotAA n = 882 |
Non-DrotAA n = 11,610 |
Total n = 12,492 |
P value |
|
|
||||
|
Discharge location by DrotAA use, n (%): |
(n = 807) |
(n = 10,537) |
(n = 11,344) |
<0.001 |
|
Died |
400 (49.6) |
5236 (49.7) |
5636 (49.7) |
|
|
Community |
236 (29.2) |
3652 (34.7) |
3888 (34.3) |
|
|
Other hospital |
73 (9.0) |
856 (8.1) |
929 (8.2) |
|
|
Extended/Chronic care Institution |
83 (10.3) |
620 (5.9) |
703 (6.2) |
|
|
Other/Unknown |
15 (1.9) |
173 (1.6) |
188 (1.7) |
|
|
Hospital mortality for DrotAA therapy, adjusted for Age, 7 OD*, Active Cancer, and Propensity Quartiles† |
Adjusted Odds Ratio |
95% Confidence Interval |
---- |
P value |
|
All patients** |
0.72 |
0.603 – 0.86 |
---- |
0.0003 |
|
|
||||
|
*Organ Dysfunction (OD). † See METHODS and Additional data file 1 for details and explanation of this covariate ** Model #9 used for this analysis. DrotAA = drotrecogin alfa (activated); PROGRESS = Promoting Global Research Excellence in Severe Sepsis. |
||||
|
Martin et al. Critical Care 2009 13:R103 doi:10.1186/cc7936 |
||||
